본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

The journal of microbiology v.43 no.2, 2005년, pp.133 - 143   피인용횟수: 3


Niyogi Swapan Kumar    (National Institute of Cholera and Enteric Diseases P-33  );
  • 초록

    Shigellosis is a global human health problem. Four species of Shigella i.e. S. dysenteriae, S. flexneri, S. boydii and S. sonnei are able to cause the disease. These species are subdivided into serotypes on the basis of O-specific polysaccharide of the LPS. Shigella dysenteriae type 1 produces severe disease and may be associated with life-threatening complications. The symptoms of shigellosis include diarrhoea and/or dysentery with frequent mucoid bloody stools, abdominal cramps and tenesmus. Shigella spp. cause dysentery by invading the colonic mucosa. Shigella bacteria multiply within colonic epithelial cells, cause cell death and spread laterally to infect and kill adjacent epithelial cells, causing mucosal ulceration, inflammation and bleeding. Transmission usually occurs via contaminated food and water or through person-to-person contact. Laboratory diagnosis is made by culturing the stool samples using selective/differential agar media. Shigella spp. are highly fragile organism and considerable care must be exercised in collecting faecal specimens, transporting them to the laboratories and in using appropriate media for isolation. Antimicrobial agents are the mainstay of therapy of all cases of shigellosis. Due to the global emergence of drug resistance, the choice of antimicrobial agents for treating shigellosis is limited. Although single dose of norfloxacin and ciprofloxacin has been shown to be effective, they are currently less effective against S. dysenteriae type 1 infection. Newer quinolones, cephalosporin derivatives, and azithromycin are the drug of choice. However, fluoroquinolone-resistant S. dysenteriae type 1 infection have been reported. Currently, no vaccines against Shigella infection exist. Both live and subunit parenteral vaccine candidates are under development. Because immunity to Shigella is serotype-specific, the priority is to develop vaccine against S. dysenteriae type 1 and S. flexneri type 2a. Shigella species are important pathogens responsible for diarrhoeal diseases and dysentery occurring all over the world. The morbidity and mortality due to shigellosis are especially high among children in developing countries. A recent review of literature (KotIoff et al.,1999) concluded that, of the estimated 165 million cases of Shigella diarrhoea that occur annually, $99\%$ occur in developing countries, and in developing countries $69\%$ of episodes occur in children under five years of age. Moreover, of the ca.1.1 million deaths attributed to Shigella infections in developing countries, $60\%$ of deaths occur in the under-five age group. Travellers from developed to developing regions and soldiers serving under field conditions are also at an increased risk to develop shigellosis.

  • 참고문헌 (115)

    1. Ashkenazi, S., G Dinari, A. Zevulunov, and M. Nitzan, 1987. Convulsions in childhood shigellosis. Clinical and laboratory features in 153 children. Am. J. Dis. Child. 141, 208-210 
    2. Ashkenazi, S., J.H. Passwell, E. Harlev, D. Miron, R. Dagan, N. Farzan, R. Ramon, E. Majady, D.A. Bryla, A.B. Karpas, J.B. Robbins, and R. Schneerson. The Israel Paediatric Shigella Study Group. 1999. Safety and immunogenecity of Shigella sonnei and Shigella flexneri 2a O specific polysaccharide conjugates in children. J. Infect. Dis. 179, 1565-1568 
    3. Bennish, M.L., M.A. Salam, R. Haider, and M. Barza 1990. Therapy for Shigellosis. II. Randomized,double-blind comparison of ciprofloxacin and ampicillin. J. Infect. Dis. 162, 711-716 
    4. Bennish, M.L. 1991. Potentially lethal complications of shigellosis. Rev. Infect. Dis. 13(Suppl. 4), S319-324 
    5. Berlutti, E, M. Casalino, C. Zagaglia, P.A. Frandiani, P. Visca, and M. Nicoletti. 1998. Expression of the virulence plasmid-carried apyrase gene (apy) of enteroinvasive Escherichia coli and Shigella flexneri is under the control of H-NS and the VirF and VirB regulatory cascade. Infect. Immun. 66, 4957-4964 
    6. Bhattacharya, M.K., G.B. Nair, D. Sen, M. Paul, A. Debnath, A. Nag, D. Dutta, P. Dutta, S.C. Pal, and S.K. Bhattacharya. 1992. Efficacy of norfloxacin for shigellosis: A double-blind randomized clinical trial. J. Diarrhoeal. Dis. Res. 10, 146-150 
    7. Bhattacharya, S.K., P. Dutta, D. Dutta, M.K. Bhattacharya, D. Sen, M.R. Saha, G.B. Nair, P. Das, S.N. Sikdar, R. Bose, and S.C. Pal. 1987. Relative efficacy of trimethoprim-sulfamethoxazole and nalidixic acid for acute invasive diarrhoea. Antimicrob. Agent Chemother. 31,837 
    8. Black, R.E., K.H. Brown, S. Becker, A.R. Alim, and I. Huq. 1982. Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. II. Incidence of diarrhoea and association with known pathogen. Am. J. Epidemiol. 115,315-324 
    9. Chakrabarti, M.K., J. Bhattacharya, M.K. Bhattacharya, G.B. Nair, S.K. Bhattacharya, and D. Mahalanabis. 1999. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta Paediatr. 88, 161-165 
    10. Cohen, D., S. Ashkenazi, M.S. Green, M. Gdalevich, G. Robin, R. Slepon, M. Yavzori, N. Orr, C. Block, I. Ashkenazi, J. Shemer, D.N. Taylor, T.L. Hale, J.C. Sadoff, D. Pavliakova, R. Schneerson, and J.B. Robbins. 1997. Double-blind vaccine-controlled randomized efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet. 349, 155-159 
    11. Du Pont, H.L., M.M. Levine, R.B. Hornick, and S.B Formal. 1989. Inoculum size in shigellosis and implications for expected mode of transmission J. Infect. Dis. 159, 1126-1128 
    12. Fontaine, A, J. Arondel, and P.J. Sansonetti. 1988. Role of Shiga toxin in the pathogenesis of bacillary dysentery studied using a tox mutant of Shigella dysenteriae type 1. Infect. Immun. 56, 3099-3109 
    13. Gangarosa, E.J., D.R. Perera, L.J. Mata, C.M. Morris, G Guzman, and L.B. Reller. 1970. Epidemic Shiga bacillus dysentery in Central America. II. Epidemiologic studies in 1969. J. Infect. Dis. 122, 181-190 
    14. Gendrel, D. and F. Moulin. 2001. Fluoroquinolones in paediatrics. Paediatr. Drugs. 3(5), 365-377 
    15. Hartman, A.B. and M.M. Venkatesan. 1998. Construction of a stable attenuated Shigella sonnei Delta virG vaccine strain, WRSS1, and protective efficacy and immunogenecity in the guinea pig keratoconjunctivitis model. Infect. Immun. 66, 4572-4576 
    16. Herrington, D.A., L. Van DeVerg, S.B. Formal, T.L. Hale, B.D. Tall, S.J. Cryz, E.C. Tramont, and M.M. Levine. 1990. Studies in volunteers to evaluate candidate Shigella vaccine: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8, 353-357 
    17. Khan, W.A., C. Seas, U. Dhar, M.A. Salam, and M.L. Bennish. 1997. Treatment of shigellosis: V. Comparison ofazithromycin and ciprofloxacin. A double-blind randomized controlled trial. Ann. Intern. Med. 126(9),697-703 
    18. Kitasato, S. 1894. The bacillus of bubonic plague. Lancet. 2, 428-430 
    19. Koster, F., J. Levin, L. Walker, K.S. Tung, R.H. Gilman, M.M. Rahaman, M.M. Majid, S. Islam, and R.C. Williams. 1978. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N. Eng. J. Med. 298, 927-933 
    20. Kristjansson, M., B. Viner, and J.N. Maslow. 1994. Polymicrobial and recurrent bacteremia with in a patient with AIDS. Scand. J. Infect. Dis. 26, 411-416 
    21. Levine, M.M., H.L. DuPont, S.B. Formal, R.B. Hornick, A. Takeuchi, E.J. Gangarosa, M.J. Snyder, and J.P. Libonati. 1973. Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J. Infect. Dis. 127, 261-270 
    22. Mata, LJ., EJ. Gangarosa, A. Caceres, D.R. Perera, and M.L. Mejicanos. 1970. Epidemic Shiga bacillus dysentery in Central America. etiologic investigations in Guatemala, 1969. J. Infect. Dis. 122, 170-180 
    23. Murphy, G, L. Bodhidatta, P Echeverria, S. Tansuphaswadikul, C. W. Hoge, S. Imlarp, and K. Tamura. 1993. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann. Intern. Med. 118, 582 
    24. Nelson, J.D., H. Kusmiesz, and L.H. Jackson. 1976. Comparison of trimethoprim/ sulphamethoxazole and ampicillin therapy for shigellosis in ambulatory patients. J. Pediatr. 89, 491 
    25. Niyogi, S.K., U. Mitra, and P. Dutta. 2001. Changing pattern of serotypes and antimicrobial susceptibilities of Shigella species isolated from children in Calcutta, India. Jpn. J. Infect. Dis. 54, 121-122 
    26. Olsson-Liljequist, B. 1992. E-test as a routine MIC tool for reference work. Diagn. Microbiol. Infect. Dis. 15, 479-482 
    27. Pal, S.C. 1984. Epidemic bacillary dysentery in West Bengal. Lancet. 1, 1462 
    28. Panhotra, B.R., B. Desai, and P.L. Sharma, 1985. Nalidixic acid resistant Shigella dysenteriae type 1. Lancet. 1, 763 
    29. Pozsgay, V., C. Chiayung, L. Pannel, J. Wolfe, J.B. Robbins, and R. Schneerson. 1999. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the a-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. USA 96, 5194-5197 
    30. Robbins, J.B, C.Y. Chu, and R. Schneerson. 1992. Hypothesis for vaccine development: Protective immunity to enteric diseases caused by non-typhoidal Salmonella and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis. 15,346-361 
    31. Sarkar, K., S. Ghosh, S.K. Niyogi, and S.K. Bhattacharya. 2003. Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolone. Lancet. 361, 785 
    32. Schuch, R. and A.T. Maurelli. 1999. The mxi-Spa type III secretory pathway of Shigella flexneri requires an outer membrane lipoprotein MxiM, for invasion translocation. Infect. Immun. 67, 1982-1991 
    33. Sen, D., P. Dutta, B.C. Deb, and S.C. Pal. 1988. Nalidixic acid resistant Shigella dysenteriae type 1 in Eastern India. Lancet. 2, 911 
    34. Shiga, K. 1906. Obsevation on the epidemiology of dysentery in Japan. Philippine J. of Sci. 1, 485-500 
    35. Sur, D., S.K. Niyogi, S. Sur, K.K. Datta, Y. Takeda, G.B. Nair, and S.K. Bhattacharya 2003. Multi-drug resistant Shigelaa dysenteriae type 1: Forerunners of a new epidemic strain in eastern India? Emerg. Inf. Dis. 9(3), 404-405 
    36. Todd, C. 1904. On a dysentery toxin and antitoxin. J. Hyg. 4, 480-494 
    37. World Health Organization. 1987. Manual for the investigation of acute enteric infections, programme for control of diarrhoeal diseases. Geneva CDD/83.3. Rev. 1 
    38. World Health Organization. 1997. New strategies for accelerating Shigella vaccine development. Weekly Epidemiol Record. 72, 73-80 
    39. Yavzori, M., D. Cohen, and N. Orr. 2002. Prevalence of the genes for shigella enterotoxin 1 and 2 among clinical isolates of shigella in Israel. Epidemiol. Infect. 128, 533-535 
    40. Bhattacharya, S.K., M.K. Bhattacharya, D. Dutta, S. Dutta, M. Deb, A Deb, K.P. Das, H. Koley, and G.B. Nair. 1997. Double blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr. 86, 319-320 
    41. Finch, M., G. Rodey, D. Lawrence, and P. Blake. 1986. Epidemic Reiters syndrome following an outbreak of shigellosis. Eur. J. Epidemiol. 2, 26-30 
    42. DuPont, H.L., C.D. Ericsson, J.J. Mathewson, E. Palazzini, M.W. DuPont, Z.D. Jiang, A. Mosavi, and F.J. de la Cabada. 1998. Rifaximin, a nonabsorbed antimicrobial, in the therapy of travelers diarrhoea. Digestion. 59, 708-714 
    43. Salam, M.A., C. Seas, W.A. Khan, and M.L. Bennish. 1995. Treatment of shigellosis: IV cefixime is ineffective in shigellosis in adults. Ann. Intern. Med. 123(7), 505-508 
    44. Shears, P. 1996. Shigella infection. Ann. Trop. Med. Parasitol. 90, 105-114 
    45. Sieper, J., J. Braun, P. Wu, R. Hauer, and S. Laitko. 1993. The possible role of Shigella in sporadic enteric reactive arthritis. Br. J. Rheumatol. 32, 582-585 
    46. Bose, R., J.N. Nashipuri, P.K. Sen, P. Dutta, S.K. Bhattacharya, D. Dutta, D. Sen, and M.K. Bhattacharya. 1984. Epidemic of dysentery in West Bengal: clinicians enigma. Lancet. 2, 1160 
    47. Butler, T., P. Speelman, I. Kabir, and J. Banwell. 1986. Colonic dysfunction during shigellosis. J. Infect. Dis. 154, 817-824 
    48. DuPont, H.L., R.B. Hornick, A.T. Dawkins, M.J. Snyder, and S.B. Formal. 1969. The response of man to virulent Shigella flexneri 2a. J. Infect. Dis. 119, 296-299 
    49. Shiga, K. 1936. The trend of prevention, therapy, and epidemiology of dysentery since the discovery of its causative organisms. N. Engl. J. Med. 215, 1205-1211 
    50. Kotloff, K.L., J.P. Winickoff, B. Ivanoff, J.D. Clemens, D.L. Swerdlow, PJ. Sansonetti, G.K. Adak, and M.M. Levine. 1999. Global burden of Shigella infection:Implications for vaccine development and implementation of control strategies. Bull. WHO. 77, 651-666 
    51. Shiga, K. 1898. Ueber den Erreger der Dysenterie in Japan. Vorlaufige Mitteilung Zentralbal Bakteriol Microbiol Hyg. 23, 599-600 
    52. Munshi, M.H., D.A. Sack, K. Halder, Z.U. Ahmed, M.M. Rahaman, and M.O. Murshed. 1987. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet. 2,419-421 
    53. Nataro, J.P., J. Seriwatana, A. Fasano, D.R Maneval, L.D. Guers, F. Noriega, F. Dubovsky, M.M. Levine, and J.G Morris, Jr. 1995. Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect. Immun. 63, 4721-4728 
    54. Ross, S., G. Controno, and W. Khan. 1972. Resistance of shigellae to ampicillin and other antibiotic. J. Am. Med. Assoc. 221, 45 
    55. Angulo, F.J. and D.L. Swerdlow. 1995. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin. Inf. Dis. 21 Suppl. 1, S84-S93 
    56. McKee, K.T. Jr, T.M Shields, P.R. Jenkins, J.M Zenilman, and G. E. Glass. 2000. Application of a geographic information system to the tracing and control of an outbreak of shigellosis. Clin. Inf. Dis. 31, 728-733 
    57. National Committee for Clinical Laboratory Standards. 1997. Performance standard antimicrobial disk susceptibility tests: approved standards. M2-A6, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa 
    58. Bhattacharya, S.K., K. Sarkar, G.B. Nair, A.S.G. Faruque, and D.A. Sack. 2003 A regional alert of multidrug-resistant Shigella dysenteriae type 1 in South Asia. The Lancet. Inf. Dis. 3, 751 
    59. Conradi, H. 1903. Uber losliche, durch aseptische auto lyse erhaltene giftstoffe von ruhrund typhus bazillen. Dtsch. Med. Wochenschr. 20, 26-28 
    60. Dorman, C.J. and M.E. Porter. 1998. The Shigella virulence regulatory cascade: a paradigm bacterial gene control mechanism. Mol. Microbiol. 29, 677-684 
    61. Shiga, K. 1898. Ueber den Dysenterie bacillus (Bacillus dysenteriae), Zentralbl Bakteriol Parasitenkd Abt I Org. 24, 817-824 
    62. Struelens, M.J., D. Patte, I. Kabir, A. Salam, S.K. Nath, and T. Butler. 1985. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J. Infect. Dis. 152, 784-790 
    63. Flexner, S. 1900. On the etiology of tropical dysentery. Bull. Johns Hopkins Hosp. 11, 231-242 
    64. Salam, M.A. and M.L. Bennish. 1988. Therapy for shigellosis I randomized double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr. 113, 901-907 
    65. Acheson, D.W.K., A. Donohue-Rolfe, and G.T. Keusch.1991. The family of Shiga and Shiga-like toxins. p. 415-433. In J E Alouf and J H Freer (ed.), Sourcebook of Bacterial Protein Toxins. Academic Press, New York 
    66. Batchelor, B.I, J.N. Kimari, and R.J. Brindle. 1996. Microbiology of HIV associated bacteraemia and diarrhoea in adults from Nairobi, Kenya. Epidemiol. Infect. 117, 139-144 
    67. Kruse, W. 1900. Ueberdie Ruhr als Volkskrankheit und ihrer erreger. Dtsch. Med. Wochenschr. 26, 637-639 
    68. Ackerman, B.H and E.A. Dello Buono. 1996. In vitro testing of anti-biotics. Pharmacotherapy 16, 201-221 
    69. Basualdo, W., and A. Arbo. 2003. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr: Infect. Dis. J. 22(4), 347-377 
    70. Noriega, F.R., Losonsky, G, Lauderbaugh, C., Liao, F.M. Wang, J.Y., and M.M. Levine. 1996. Engineered guaB-A virG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenecity, and potential efficacy as a mucosal vaccine. Infect. Immun. 64, 3055-3061 
    71. Rahaman, M.M., M.M. Khan, K.M.S. Aziz, M.S. Islam, and A.K. Kibriya. 1975. An outbreak of dysentery caused by Shigella dysenteriae type 1 on a coral island in the bay of Bengal. J. Infect. Dis. 132, 15- 
    72. Ashkenazi, S, J. Amir, Y. Waisman, A. Rachmel, B.Z. Garty, Z. Samra, I. varsano, and M.M. Nitzan. 1993. A randomized, double-blind study compairing cefixime and trimethoprim-sulphamethoxazole in the treatment of childhood shigellosis. J. Paediatr. 123, 817-821 
    73. Coster, T.S., C.W. Hoge, L.L. Van DeVerg, AB. Hartman, E.V. Oaks, M.M. Venkatesan, D. Cohen, G Robin, AF. Thompson, P.J. Sansonetti, and T.L. Hale. 1999. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67, 3437-3443 
    74. Keusch, G. T. 1998. The rediscovery of Shiga toxin and its role in clinical disease. Jpn. J. Med. Sci. Biol. 51(Suppl. I), S5-S22 
    75. Trofa, A.F., H. Ueno-Olsen, R. Oiwa, and M. Yoshikawa. 1999. Dr. Kiyoshi Shiga: Discoverer of the dysentery bacillus. Clin. Infect. Dis. 29, 1303-1306 
    76. Salam, M.A. and M.L. Bennish. 1991. Antimicrobial therapy for shigellosis. Rev. Infect. Dis. 13(Suppl 4), S332-S341 
    77. Venkatesan, M., P.C. Fernandez, J.M. Buysee, S.B. Formal, and T.L. Hale. 1991. Virulence phenotype and genetic characteristics of the T32-1STRATI Shigella flexneri 2a vaccine strain. Vaccine 9, 358-363 
    78. Bennish, M.L., and B.J. Wojtyniak. 1991. Mortality due to shigellosis: community and hospital data. Rev. Infect. Dis. 13(Suppl. 4), S245-251 
    79. Drusin, L.M. G Genvert, B. Topf-Olstein, and E. Levy-Zombeck. 1976. Shigellosis: Another sexually transmitted disease? Br. J. Vener. Dis. 52, 348-350 
    80. Way, S.S., A.C. Borczuk, R. Dominit, and M.B. Goldberg. 1998. An essential role for gamma interferon in inate resistance to Shigella flexneri infection. Infect. Immun. 66, 1342-1348 
    81. Bhattacharya, S.K., M.K. Bhattacharya, P. Dutta, D. Sen, R. Rasaily, A. Moitra, and S.C. Pal. 1991. Randomized clinical trial of norfloxacin for shigellosis. Am. J. Trop. Med. Hyg. 45, 683-687 
    82. Cohen, D., M.S. Green, C. Block, R. Slepon, and Y. Lerman. 1992. Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide. J. Infect. Dis. 165, 785-787 
    83. Obituary. The New York Times 1957 26 Jan. sec. 19,6 
    84. Guan, S. and N.K. Verma. 1998. Serotype conversion of a Shigella flexneri candidate vaccine strain via a novel site-specific chromosome-intigration system. FEMS Microbiol. Lett. 166, 79-87 
    85. Hale, T.L. 1991. Genetic basis of virulence in Shigella species. Microbiol. Rev. 55, 206-224 
    86. Kotloff, K.L., F.R. Noriega, T. Samandari, M.B. Sztein, G.A. Losonsky, J.P. Nataro, W.D. Picking, E.M. Barry, and M.M. Levine. 2000. Shigellaflexneri 2a strain CVD 1207, with specific deletions in, virG, sen, set, and gua BA, is highly attenuated in humans. Infect. Immun. 68, 1034-1039 
    87. Mounier, J., V. Laurent, A. Hall, P. Fort, M.E. Carlier, P.J. Sansonetti, and C. Egile. 1999. Rho family Gl'Pases control entry of Shigella flexneri into epithelial cells but not intracellular motility. J. Cell Sci. 112, 2069-2080 
    88. Way, S.S. and M.B. Goldberg. 1998. Clearence of Shigellaflexneri occurs through a nitric oxide independent mechanism. Infect. Immun. 66, 3012-3016 
    89. Finlay, B.B. and S.Falkow. 1997. Common themes in microbial pathogenecity revisited. Microbiol. Mol. Biol. Rev. 61, 136-169 
    90. Robbins, J.B, R. Schneerson, and S.C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious disease by inactivating the inoculum. J. Infect. Dis. 171, 1378-1398 
    91. Sansonetti, P.J. and C. Egile. 1998. Molecular bases of epithelial cell invasion by Shigella flexneri? Antonie Van Leeewenhoek. 74, 191-197 
    92. Vargas, M., J. Gascon, M.T. Jimenez, De Anta., and J. Vila. 1999. Prevalence of Shigella enterotoxins 1 and 2 among Shigella strains isolated from patients with travelers diarrhoea. J. Clin. Microbiol. 37, 3608-3611 
    93. World Health Organization. 2001. Antimicrobial resistance in shigellosis, cholera and campylobacteriosis. WHO/CDS/CSR/ DRS/2001.8. World Health Organization, Geneva, Switzerland 
    94. Bhattacharya, S.K., and D. Sur. 2003. An evaluation of current shigellosis treatment. Expert Opin. Pharmacothe. 4(8), 1315-1320 
    95. Mathan, V.I. and M.M. Mathan. 1991. Intestinal manifestations of invasive diarrhoeas and their diagnosis. Rev. Infect. Dis. 13 (Suppl 4), S311-313 
    96. Nhieu, G.T. and P.J. Sansonetti. 1999. Mechanism of Shigella entry into epithelial cells. Curr. Opin. Microbiol. 2, 51-56 
    97. World Health Organization. 1995. The treatment of diarrhoea. A manual for physicians and other senior health workers. Geneva, Switzerland (WHO/CDR/95.3) 
    98. Ferreccio, C., V. Prado, A. Ojeda, M. Cayyazo, P. Abrego, L. Guers, and M.M. Levine. 1991.Epidemiologic patterns of acute diarrhoea and endemic Shigella infections in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol. 134, 614-627 
    99. Hong, M., M. Gleason, E.E. Wyckoff, and S.M. Payne. 1998. Identification of two Shigellaflexneri chromosomal loci involved in intercellular spreading. Infect. Immun. 66, 4700-4710 
    100. Varsano, I., T. Elditz-marcus, M. Nussinovch, and I. Elian. 1991. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J. Pediatr. 118, 627-632 
    101. McCormack, B.A., A.M. Siber, and A.T. Maurerelli. 1998. Requirement of the Shigella flexneri virulent plasmid in the ability to induce trafficking of neutrophils across polarized monolayers of the intestinal epithelium. Infect. Immun. 66, 4237-4243 
    102. Noriega, F.R., P.M. Liao, S.B. Formal, A. Fasano, and M.M. Levine. 1995. Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes. J. Infect. Dis. 172, 1408-1410 
    103. Sansonetti, P.J. and J. Arondel. 1989. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 7, 443-450 
    104. Shiga, K. and K. Kanwa. 1950. Tokyo: Nihon Iji Shimpo Shuppanbu 
    105. Behring. E. and S. Kitasato. 1890. Ueber das Zustandkommen der Diphtherie-Immunitaet und der Tetanus-Immunitaet bei Thieren. Dtsch. Med. Wochenschr. 49,1-6 
    106. Formal, S.B., R.M. Maenza, S. Austin, and E.H. LaBrec. 1967. Failure of parenteral vaccine to protect monkeys against experimental shigellosis. Proc. Soc. Exp. Biol. Med. 125, 347-349 
    107. Levine, M.M. 1991. Shigellosis. In: Strickland G.T, HuntersTropical Medicine. 7th Edition. Philadelphia, WB Saunders Co., 340-344 
    108. Sack, R.B., M. Rahman, M. Yunus, and E.H. Khan. 1997 Antimicrobial resistance in organisms causing diarrhoeal disease. Clin. Infect. Dis. 24(suppl. 1), S102-105 
    109. Bergey's manual of Determinative Bacteriology. 3rd ed. Williams & Wilkins Co., Baltimore, Maryland 1930: 357-363 
    110. Gotuzzo, E., R.A. Oberhelman, C. Maguina, S.J. Berry, A. Yi, M. Guzman, R. Ruiz, R. Leon-Barua, and B. Sack. 1989. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulphamethoxazole for acute shigellosis in adults. Antimicrob. Agents Chemother. 33, 1101-1104 
    111. Kotloff, K.L., J.P. Nataro, G.A. Losonsky, S.S. Wasserman, T.L. Hale, D.N. Taylor, J.C. Sadoff, and M.M. Levine. 1995. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine. 13, 1488-1494 
    112. Levine, M.M. 1986. Antimicrobial therapy for infectious diarrhoea. Rev. Infect. Dis. 8, S207-S216 
    113. Levine, O.S. and M.M. Levine. 1991. House flies (Musca domestica) as mechanical vectors of shigellosis. Rev. Infect. Dis. 13, 688-696 
    114. Niyogi, S.K., M. Vargas, and J. Vila. 2004. Prevalence of the sat,set and sen genes among diverse serotypes of Shigella flexneri strains isolated from patients with acute diarrhoea. Clin. Microbiol. Infect. 10, 574-576 
    115. Taylor, D., P. Echeverria, T. Pal, O. Sethabutr, S. Saiborisuth, S. Sricharmorn, B. Rowe, and J. Cross. 1986. The role of Shigella spp., enteroinvasive Escherichia coli and other enteropathogens as cause of childhood dysentery in Thailand. J. Infect. Dis. 153, 1132-1138 
  • 이 논문을 인용한 문헌 (3)

    1. 2006. "" Journal of bacteriology and virology : JBV, 36(2): 41~49     
    2. Park, Hong-Ki ; Jung, Eun-Young ; Jung, Jong-Moon ; Yu, Pyung-Jong 2007. "Detection and Distribution of Bacterial Pathogens in Raw Water and During Water Treatment Process by Polymerase Chain Reaction" 생명과학회지 = Journal of life science, 17(10): 1374~1380     
    3. 2010. "" The journal of microbiology, 48(2): 236~242     

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역


  • NDSL :

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기